

# Plasma renin levels: the lower the better in terms of cardiovascular risk?

Bernard Waeber\* and François Feihl

Division of Clinical Pathophysiology, University Hospital and Faculty of Biology and Medicine, University of Lausanne, CH-1011 Lausanne, Switzerland

Online publish-ahead-of-print 4 October 2012

**This editorial refers to ‘Plasma renin and outcome in the community: data from PREVEND’<sup>†</sup>, by R.A. de Boer et al., on page 2351 of Volume 33 Number 18 September 2012**

In 1898, Tigerstedt and Bergman discovered that a cortical extract of rabbit kidney has vasopressive properties when injected intravenously.<sup>1</sup> This is how a long and beautiful story started, leading to characterization of the renin–angiotensin–aldosterone system and to elucidation of its physiological and pathophysiological functions.<sup>2–5</sup> Presently, blockers of this system play a prominent role in the treatment of arterial hypertension, heart failure, diabetes, and nephropathy.<sup>6,7</sup>

Considerable progress was made when it became possible to assay renin in blood.<sup>2–5</sup> The regulation of renin secretion is complex, with a key role played by sodium balance. In man, the blood concentration of renin is inversely related to oral sodium intake. This relationship was taken into account in two studies seeking to evaluate cardiovascular risk in hypertensive patients, using stratification according to plasma renin activity level (low, normal, and high). The first study, by H.R. Brunner and colleagues, showed an association of abnormally high renin secretion and increased risk of stroke or myocardial infarction.<sup>8</sup> Subsequently, these results were challenged, and two decades elapsed before their corroboration by Alderman and colleagues.<sup>9</sup> These authors reported that subjects with high plasma renin were at increased risk of cardiovascular events, notably myocardial infarction, results that were more convincing than the initial observations, due to a patient population (1717 hypertensive patients, as compared with 219 in the initial study). Nevertheless, this new result did not end the controversy surrounding the potentially deleterious impact of renin on cardiovascular risk.<sup>10</sup> Therefore, we must ponder on the best option for antihypertensive therapy. Is there any advantage in blocking the renin–angiotensin system of all patients, or should we target only those in whom renin is most likely to be elevated, based on criteria such as age? Should we be wary of stimulating the

renin–angiotensin system if we prescribe a diuretic alone without a blocker of this system?<sup>11</sup>

The recent study by de Boer and colleagues provides the best evidence to date that plasma renin concentration has a prognostic value for the occurrence of cardiovascular events, independent of blood pressure level.<sup>12</sup> Several features of this work are worth mentioning. (i) The investigated cohort comprises a large number of adults ( $n = 6228$ ), all living in the same city and having responded favourably to a written invitation for participation sent to all inhabitants of this city. The results are therefore likely to be representative for a general urban western population. (ii) Subjects were followed for an extensive period, on average  $\sim 10$  years. (iii) Enrolment was not restricted to hypertensive subjects, but was also open to normotensive subjects who had not incurred any cardiovascular complication such as stroke at the time of inclusion. (iv) When the cohort was subdivided according to quintiles of renin levels, the subgroups did not differ with respect to blood pressure and 24 h sodium excretion, making it possible to study the association of renin level with cardiovascular outcome independently of blood pressure and dietary sodium intake.

What do the results tell us? That high circulating renin levels are associated with increased cardiovascular morbidity and mortality, even after correcting for traditional risk factors.

From a clinical viewpoint, this observation is all the more relevant since it concerns a population of both hyper- and normotensive subjects. In this study, plasma renin levels were measured; these are known to correlate with plasma renin activity. Increased renin secretion is expected to augment the circulating concentrations of angiotensin II and perhaps also the production of angiotensin II at the tissue level.<sup>13</sup> It is to be regretted that the authors have not taken advantage of their enormous data bank also to assay active renin and prorenin, the latter being potentially involved in the tissue production of angiotensin II.<sup>14,15</sup> Wherever it is formed, this peptide plays a crucial role in the pathogenesis of vascular disease, in particular by inducing oxidative stress, which in turn triggers an inflammatory response.<sup>16</sup>

The opinions expressed in this article are not necessarily those of the Editors of the *European Heart Journal* or of the European Society of Cardiology.

\* Corresponding author. Tel: +41 21 314 07 60, Fax: +41 21 314 25 18, Email: [Bernard.Waeber@chuv.ch](mailto:Bernard.Waeber@chuv.ch)

<sup>†</sup> doi:10.1093/eurheartj/ehs198.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2012. For permissions please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

The treated hypertensive participants ( $n = 843$ ) have not been taken into account in the primary analysis, but have been used for a subanalysis. In these patients, renin levels had no link to cardiovascular risk. Perhaps there were too few of them. The most likely explanation relates to the diverse effects of various antihypertensive agents on renin secretion. Whereas diuretics stimulate the renin–angiotensin system, beta-blockers—if devoid of intrinsic sympathomimetic activity—act in the opposite direction. Dihydropyridine-type calcium antagonists tend to increase renin secretion, but most often only transiently at the onset of treatment. Regarding angiotensin-converting enzyme inhibitors and antagonists of angiotensin II, they induce hyper-reninaemia, due to the inactivation of the negative feedback control normally exerted on renin secretion by angiotensin II. Here, a few thoughts are in order. Can monotherapy with diuretics be truly beneficial, considering that such therapy stimulates the renin–angiotensin system? If optimal prevention of cardiovascular complications is our goal, should we not systematically associate an antagonist of the renin–angiotensin system with a diuretic? Unfortunately, no answer to these questions is yet available. At the very most, we know that concomitant blockade of the renin–angiotensin system attenuates the metabolic effects of diuretics, which should be favourable in the long term.

The main message of the study by de Boer *et al.* is to confirm the association of high renin levels and increased cardiovascular risk. Based on this fact, some might propose the systematic assay of plasma renin as an additional tool for refining the stratification of cardiovascular risk. More practically, prescribing a blocker of the renin–angiotensin system could be considered in every patient with either hypertension, heart failure, or kidney disease, without determining the renin status. Such an approach would be expected to be of benefit not only to patients with high renin levels, but also to those with normal or low renin levels.

**Conflict of interest:** none declared.

## References

1. Tigerstedt R, Bergman PG. Niere und Kreislauf. *Skand Arch Physiol* 1898;**8**: 2234–2271.
2. Oparil S, Haber E. The renin-angiotensin system (first of two parts). *N Engl J Med* 1974;**291**:389–401.
3. Davis JO, Freeman RH. Historical perspectives on the renin-angiotensin-aldosterone system and angiotensin blockade. *Am J Cardiol* 1982;**49**:1385–1389.
4. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. *Am J Med Sci* 2003;**326**:15–24.
5. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. *Cardiovasc Drugs Ther* 2010;**24**:341–344.
6. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. *J Hypertens Suppl* 2005;**23**:S9–S17.
7. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. *J Am Soc Nephrol* 2002;**13** Suppl 3:S173–S178.
8. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. *N Engl J Med* 1972;**286**:441–449.
9. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. *N Engl J Med* 1991;**324**:1098–1104.
10. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. *Eur Heart J* 2007;**28**:2644–2652.
11. Brown MJ. Renin: friend or foe? *Heart* 2007;**93**:1026–1033.
12. de Boehr RA, Schrotten NF, Bakker SJL, Mahmud H, Szymanski MK, van der Harst P, Gansevoort RT, van Veldhuisen D, van Gilst WH, Hillege HL. Plasma renin and outcome in the community: data from PREVEND. *Eur Heart J* 2012;**33**:2351–2359.
13. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. OA review of experimental evidence. *Circulation* 1994;**89**:458–470.
14. Nguyen G, Delarue F, Burckle C, Bouzahir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J Clin Invest* 2002;**109**:1417–1427.
15. Krop M, Danser AH. Circulating versus tissue renin–angiotensin system: on the origin of (pro)renin. *Curr Hypertens Rep* 2008;**10**:112–118.
16. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. *Hypertension* 2001;**37**:1047–1052.